As a groundbreaking advancement in cancer immunotherapy, chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized treatment options for patients with hematologic malignancies. Based on the Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products Guidance for Industry, this study systematically analyzes key clinical trial data from seven FDA-approved CAR-T products as of 2024. The analysis provides detailed discussion on several pivotal aspects including single-arm trial design and control settings, recommended dosing strategies, as well as safety and efficacy evaluation methodologies. While CAR-T therapy has demonstrated remarkable clinical success, future development directions encompass expansion into solid tumors, exploration of novel targets, advancement of universal CAR-T technologies, optimization of combination therapies, and integration of emerging technologies such as artificial intelligence, all of which will collectively drive the high-quality development of the CAR-T industry.